Get access

Clinical Use of Cooled Radiofrequency Ablation

Authors


  • Dr. Stevenson is a consultant to Biosense-Webster and has received speaking honoraria from Boston Scientific, St. Jude Medical, and Medtronic. Dr. Seiler has received a research grant from St. Jude Medical.

  • Manuscript received 4 February 2008; Revised manuscript received 1 March 2008; Accepted for publication 3 March 2008.

  • Section Editor: Hugh Calkins, M.D.

Address for correspondence: William G. Stevenson, M.D., Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA. Fax: 617-277-4981; E-mail: wstevenson@partners.org

Abstract

Irrigated (cooled) radiofrequency (RF) ablation has become our primary ablation tool for treating atrial fibrillation, macroreentrant atrial tachycardias, and scar-related ventricular tachycardias. As with any technology that increases ablation lesion size, there is the potential for increased risk. The methods described are a cautious approach to power titration that considers the risks of excessive heating and the lesion size needed for a particular site. Future methods of assessing lesion creation will hopefully refine energy titration to improve safety and efficacy of cooled RF ablation.

Get access to the full text of this article

Ancillary